Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.

MLA

Lynch, Ryan C., et al. “Dose-Dense Brentuximab Vedotin plus Ifosfamide, Carboplatin, and Etoposide for Second-Line Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma: A Single Centre, Phase 1/2 Study.” The Lancet. Haematology, vol. 8, no. 8, Aug. 2021, pp. e562–71. EBSCOhost, https://doi.org/10.1016/S2352-3026(21)00170-8.

APA

Lynch, R. C., Cassaday, R. D., Smith, S. D., Fromm, J. R., Cowan, A. J., Warren, E. H., Shadman, M. S., Shustov, A., Till, B. G., Ujjani, C. S., Libby, E. N., 3rd, Philip, M., Coye, H., Martino, C. N., Bhark, S. L., Morris, K., Rasmussen, H., Behnia, S., Voutsinas, J., & Gopal, A. K. (2021). Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study. The Lancet. Haematology, 8(8), e562–e571. https://doi.org/10.1016/S2352-3026(21)00170-8

Chicago

Lynch, Ryan C, Ryan D Cassaday, Stephen D Smith, Jonathan R Fromm, Andrew J Cowan, Edus H Warren, Mazyar S Shadman, et al. 2021. “Dose-Dense Brentuximab Vedotin plus Ifosfamide, Carboplatin, and Etoposide for Second-Line Treatment of Relapsed or Refractory Classical Hodgkin Lymphoma: A Single Centre, Phase 1/2 Study.” The Lancet. Haematology 8 (8): e562–71. doi:10.1016/S2352-3026(21)00170-8.